Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical    BMRN

BIOMARIN PHARMACEUTICAL (BMRN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/16/2017 11/17/2017 11/20/2017 11/21/2017 11/22/2017 Date
82.56(c) 82.88(c) 82.95(c) 82.91(c) 82.99(c) Last
848 395 970 932 1 124 036 599 845 481 784 Volume
+0.92% +0.39% +0.08% -0.05% +0.10% Change
More quotes
Financials ($)
Sales 2017 1 302 M
EBIT 2017 -111 M
Net income 2017 -117 M
Finance 2017 157 M
Yield 2017 -
Sales 2018 1 486 M
EBIT 2018 -34,3 M
Net income 2018 -56,9 M
Finance 2018 285 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 11,1x
EV / Sales2018 9,62x
Capitalization 14 575 M
More Financials
Company
BioMarin Pharmaceutical, Inc. is a biotechnology company that develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions.Its products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.The company was founded by Christopher M. Starr and Grant W.... 
Sector
Pharmaceuticals
Calendar
11/29 | 05:00pmPresentation
More about the company
Surperformance© ratings of BioMarin Pharmaceutical
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL
11/02 BIOMARIN PHARMACEUTICAL : to Attend Three Upcoming Investor Conferences
10/31 BIOMARIN PHARMACEUTICAL : Management's Discussion and Analysis of Financial Cond..
10/31 BIOMARIN PHARMACEUTICAL : to Attend Three Upcoming Investor Conferences
10/30 BIOMARIN PHARMACEUTICAL : FDA Grants Breakthrough Therapy Designation for BioMar..
10/27 BIOMARIN PHARMACEUTICAL INC. (NASDAQ : BMRN) Files An 8-K Results of Operations ..
10/27 BIOMARIN PHARMACEUTICAL : Adgero Biopharmaceuticals Appoints John Liatos as Chie..
10/26 BIOMARIN PHARMACEUTICAL : reports 3Q loss
10/26 BIOMARIN PHARMACEUTICAL INC : Results of Operations and Financial Condition, Fin..
10/26 BIOMARIN PHARMACEUTICAL : Highlights Breadth of Innovative Development Pipeline ..
10/26 BIOMARIN PHARMACEUTICAL : Announces Third Quarter 2017 Financial Results
More news
Sector news : Biopharmaceuticals
10:27a German chemicals companies should review British ops - trade body
08:49aDJGLAXOSMITHKLINE : Files Additional Trelegy Ellipta Application to FDA
11/22 BAYER : Brazil pushes back decision on Bayer-Monsanto tie-up
11/22 European shares retreat on euro bounce; UK flat after budget
11/22 FTSE gets sterling boost, land purchase threat dents housebuilders
More sector news : Biopharmaceuticals
News from SeekingAlpha
11/21 Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update
11/20 BIOMARIN PHARMACEUTICAL : Appeal Improves, Not A Buyer Yet
11/20 SPARK THERAPEUTICS : Buy The Dip
11/16 SPY : How Much Risk Do You Need To Take To Beat It?
11/16 FDA OKs Roche's Hemlibra for hemophilia A
Chart BIOMARIN PHARMACEUTICAL
Duration : Period :
BioMarin Pharmaceutical Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Technical analysis trends BIOMARIN PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 113 $
Spread / Average Target 36%
EPS Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Daniel K. Spiegelman Chief Financial Officer & Executive Vice President
Robert A. Baffi Executive Vice President-Technical Operations
Henry J. Fuchs President-Worldwide Research
Eduardo E. Von Pervieux Chief Information Officer & Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICAL0.18%14 575
BIOGEN18.26%65 516
CSL LIMITED43.07%49 706
ALEXION PHARMACEUTICALS-11.69%24 039
GRIFOLS SA33.08%18 690
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 794